MX2010005960A - Biomarcadores de braf. - Google Patents

Biomarcadores de braf.

Info

Publication number
MX2010005960A
MX2010005960A MX2010005960A MX2010005960A MX2010005960A MX 2010005960 A MX2010005960 A MX 2010005960A MX 2010005960 A MX2010005960 A MX 2010005960A MX 2010005960 A MX2010005960 A MX 2010005960A MX 2010005960 A MX2010005960 A MX 2010005960A
Authority
MX
Mexico
Prior art keywords
braf
biomarkers
disease
methods
erk2
Prior art date
Application number
MX2010005960A
Other languages
English (en)
Inventor
William T Windsor
Jason S Simon
Thomas J Hosted
Lorenzo Marc M De
Donna Marie Carr
Ahmed A Samatar
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2010005960A publication Critical patent/MX2010005960A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención provee, entre otras cosas, métodos para predecir la sensibilidad de una enfermedad, tal como cáncer, a un inhibidor de ERK1 o ERK2 o MEK detectando la presencia de un alelo de BRAF en células que median la enfermedad; se proveen también métodos de tratamiento.
MX2010005960A 2007-11-30 2008-11-26 Biomarcadores de braf. MX2010005960A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99135107P 2007-11-30 2007-11-30
US3461508P 2008-03-07 2008-03-07
PCT/US2008/084858 WO2009073513A1 (en) 2007-11-30 2008-11-26 Braf biomarkers

Publications (1)

Publication Number Publication Date
MX2010005960A true MX2010005960A (es) 2010-06-11

Family

ID=40521987

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005960A MX2010005960A (es) 2007-11-30 2008-11-26 Biomarcadores de braf.

Country Status (6)

Country Link
US (1) US20110158944A1 (es)
EP (1) EP2220503A1 (es)
JP (3) JP5603777B2 (es)
CA (1) CA2706453A1 (es)
MX (1) MX2010005960A (es)
WO (1) WO2009073513A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009073513A1 (en) * 2007-11-30 2009-06-11 Schering Corporation Braf biomarkers
US9229008B2 (en) 2008-08-19 2016-01-05 Merck Sharp & Dohme Corp. IL-8 level as a determinant of responsivity of a cancer to treatment
KR101977875B1 (ko) * 2010-04-19 2019-05-13 바이오마커 스트레터지스 엘엘씨 약물 감응성, 내성, 및 질환 진행성을 예측하기 위한 조성물 및 방법
US20140031383A1 (en) 2011-02-08 2014-01-30 Dana-Farber Cancer Institute, Inc. Methods for treatment of melanoma
EP2508184A1 (en) * 2011-04-06 2012-10-10 Æterna Zentaris GmbH Pyridopyrazine derivatives and their use
AU2012253525B2 (en) * 2011-05-10 2016-09-22 Brunangelo Falini Hairy cell leukemia biomarkers and methods of using same
JP6153758B2 (ja) * 2012-04-20 2017-06-28 アークレイ株式会社 多型検出用プローブ、多型検出方法、薬効判定方法及び多型検出用キット
US10077474B2 (en) 2012-05-29 2018-09-18 Abbott Molecular, Inc. Method of designing primers, method of detecting single nucleotide polymorphisms (SNPs), method of distinguishing SNPs, and related primers, detectable oligonucleotides, and kits
EP2984185B1 (en) 2013-04-08 2019-06-12 Merck Sharp & Dohme Corp. Methods and compositions for treating cancer
EP3719137A1 (en) * 2013-09-05 2020-10-07 Memorial Sloan-Kettering Cancer Center Ddx43 as a biomarker of resistance to mek1/2 inhibitors
US9694033B2 (en) 2014-01-24 2017-07-04 The Cleveland Clinic Foundation IL-9 secreting CD8+ Tc9 cells and methods of treating cancer
WO2015191857A1 (en) * 2014-06-13 2015-12-17 Dana-Farber Cancer Institute, Inc. Erk1 and erk2 mutations that confer resistance to mapk pathway inhibitors
WO2020132409A1 (en) 2018-12-20 2020-06-25 Trustees Of Boston University Stk19 inhibitors for treatment of cancer
US11879010B2 (en) 2021-09-30 2024-01-23 The Charlotte Mecklenburg Hospital Authority Methods and compositions for pretargeted immunotherapy
WO2023190967A1 (ja) * 2022-03-31 2023-10-05 Ｃｈｏｒｄｉａ Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社 イミダゾ［４，５－ｂ］ピリジン誘導体による固形癌治療のためのバイオマーカー

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378233B2 (en) * 2003-04-12 2008-05-27 The Johns Hopkins University BRAF mutation T1796A in thyroid cancers
DK1966151T3 (da) * 2005-12-13 2012-01-30 Schering Corp Polycykliske indazolderivater, der er ERK-hæmmere
CA2642762A1 (en) * 2006-02-16 2007-08-30 Schering Corporation Pyrrolidine derivatives as erk inhibitors
AU2007245495A1 (en) * 2006-04-26 2007-11-08 Astex Therapeutics Limited Imidazo[4, 5-b]pyridin-2-one and oxazolo[4, 5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds
US7601852B2 (en) * 2006-05-11 2009-10-13 Kosan Biosciences Incorporated Macrocyclic kinase inhibitors
WO2009073513A1 (en) * 2007-11-30 2009-06-11 Schering Corporation Braf biomarkers

Also Published As

Publication number Publication date
JP2014221063A (ja) 2014-11-27
WO2009073513A1 (en) 2009-06-11
JP2011507490A (ja) 2011-03-10
US20110158944A1 (en) 2011-06-30
JP2013031455A (ja) 2013-02-14
JP5603777B2 (ja) 2014-10-08
CA2706453A1 (en) 2009-06-11
EP2220503A1 (en) 2010-08-25

Similar Documents

Publication Publication Date Title
MX2010005960A (es) Biomarcadores de braf.
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
EA201390149A1 (ru) Способы выявления заболевания или патологических состояний с использованием фагоцитарных клеток
EP2582847A4 (en) METHOD AND MATERIALS FOR EVALUATING THE LOSS OF HETEROZYGOTY
NZ606725A (en) Methods for predicting anti-cancer response
WO2010001419A3 (en) Copy number variations predictive of risk of schizophrenia
EP2576837A4 (en) CIRCULATING NUCLEIC ACID BIOMARKERS ASSOCIATED WITH PROSTATE CANCER
MX340453B (es) Biomarcadores para cancer de pulmon.
CL2011003129A1 (es) Procedimiento para determinar riesgo de padecer enfermedad cardiovascular que comprende determinar la presencia de polimorfismos de un solo nucleotido (snp)
EP2611941A4 (en) GENESIS OF CANCER DIAGNOSIS AND PROGNOSIS
MX2013005762A (es) Biomarcadores para la prediccion de la eficacia de una inmunoterapia contra el cancer.
ATE527385T1 (de) Mit tumoren assoziierte genetische variationen
TW200636075A (en) Detection of nucleic acid variation by cleavage-amplification method
HK1133080A1 (en) Underfill detection system for an electrochemical biosensor
EP2598873A4 (en) BIOMARKERS OF PROSTATE CANCER AND METHODS USING THEM
MX2013000502A (es) Metodos y kits para el diagnostico de cancer de prostata.
MX353428B (es) Métodos y composiciones para identificar y tratar lupus.
MX2010004566A (es) Prueba de deteccion de bordetella.
MX2009013646A (es) Metodos de diagnostico y tratamiento del cancer.
MX336093B (es) Deteccion y enumeracion de microorganismos.
WO2013106844A3 (en) Methods and compositions for the treatment and diaginosis of pancreatic cancer
DK1851322T3 (da) Fremgangsmåde til enantioselektiv enzymatisk reduktion af ketoforbindelser
WO2010040083A3 (en) Gene expression predictors of chemoresistance
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
GB2480980A (en) Methods for predicting cancer response to EGFR inhibitors

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: MOTOROLA MOBILITY, INC.

FG Grant or registration